Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. The company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease; ORILISSA for the management of moderate to severe endometriosis pain in women; and ORIAHNN, a non-surgical oral medication option for the management of heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. Its product candidates in clinical development include NBI-921352 for treating pediatric patients, as well as adult focal epilepsy indications; and NBI-827104 to treat rare pediatric epilepsy and essential tremor. The company's products in clinical development also comprise NBI-1065845 for the treatment of major depressive disorder; NBI-1065846 for treating anhedonia in major depressive disorder; and NBI-118568 for the treatment of schizophrenia. It has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. Neurocrine Biosciences, Inc. was incorporated in 1992 and is headquartered in San Diego, California.
Over the last 12 months, insiders at Neurocrine Biosciences, Inc. have bought $0 and sold $106.43M worth of Neurocrine Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Neurocrine Biosciences, Inc. have bought $0 and sold $54.55M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 59,000 shares for transaction amount of $351,345 was made by BVF PARTNERS L P/IL (10 percent owner) on 2011‑10‑12.
2024-05-31 | Sale | Delaet Ingrid | Chief Regulatory Officer | 273 0.0003% | $136.55 | $37,278 | -0.62% | |
2024-05-29 | Sale | SHERWIN STEPHEN A | director | 40,000 0.0394% | $133.46 | $5.34M | +0.03% | |
2024-05-17 | Sale | POPS RICHARD F | director | 2,100 0.0021% | $141.84 | $297,860 | -5.07% | |
2024-05-17 | Sale | Sharp Shalini | director | 1,106 0.0011% | $141.90 | $156,943 | -5.07% | |
2024-05-17 | Sale | Norwalk Leslie V | director | 1,106 0.0011% | $141.82 | $156,850 | -5.07% | |
2024-05-15 | Sale | ABERNETHY MATT | Chief Financial Officer | 15,000 0.0147% | $140.24 | $2.1M | -4.73% | |
2024-05-14 | Sale | LYONS GARY A | director | 12,500 0.0122% | $135.63 | $1.7M | -2.14% | |
2024-05-14 | Sale | ABERNETHY MATT | Chief Financial Officer | 15,000 0.0146% | $135.66 | $2.03M | -2.14% | |
2024-05-06 | Sale | Delaet Ingrid | Chief Regulatory Officer | 273 0.0003% | $140.55 | $38,370 | -3.92% | |
2024-04-15 | Sale | BENEVICH ERIC | Chief Commercial Officer | 12,587 0.0128% | $133.36 | $1.68M | +3.78% | |
2024-04-01 | Sale | Delaet Ingrid | Chief Regulatory Officer | 272 0.0003% | $137.30 | $37,346 | -2.82% | |
2024-03-21 | Sale | Delaet Ingrid | Chief Regulatory Officer | 5,000 0.0051% | $145.06 | $725,320 | -4.16% | |
2024-03-14 | Sale | BENEVICH ERIC | Chief Commercial Officer | 69,521 0.0689% | $139.38 | $9.69M | -0.97% | |
2024-03-14 | Sale | MORROW GEORGE J | director | 40,000 0.0396% | $139.42 | $5.58M | -0.97% | |
2024-03-13 | Sale | POPS RICHARD F | director | 23,200 0.0231% | $140.33 | $3.26M | -2.75% | |
2024-03-13 | Sale | Delaet Ingrid | Chief Regulatory Officer | 3,000 0.003% | $140.14 | $420,419 | -2.75% | |
2024-03-11 | Sale | POPS RICHARD F | director | 100 0.0001% | $140.00 | $14,000 | -0.50% | |
2024-03-11 | Sale | Delaet Ingrid | Chief Regulatory Officer | 200 0.0002% | $140.00 | $28,000 | -0.50% | |
2024-03-08 | Sale | POPS RICHARD F | director | 1,700 0.0017% | $140.05 | $238,078 | -0.84% | |
2024-03-08 | Sale | Delaet Ingrid | Chief Regulatory Officer | 1,800 0.0018% | $140.03 | $252,053 | -0.84% |
GORMAN KEVIN CHARLES | Chief Executive Officer | 514596 0.516% | $135.83 | 0 | 58 | |
LYONS GARY A | director | 116947 0.1971% | $135.83 | 0 | 45 | |
Gano Kyle | Chief Business Development Off | 135166 0.1363% | $135.83 | 0 | 49 | |
RASTETTER WILLIAM H | director | 51741 0.0527% | $135.83 | 0 | 7 | |
BENEVICH ERIC | Chief Commercial Officer | 40778 0.0403% | $135.83 | 0 | 39 | |
Lippoldt Darin | Chief Legal Officer | 39740 0.0394% | $135.83 | 0 | 53 | |
ABERNETHY MATT | Chief Financial Officer | 31528 0.0309% | $135.83 | 0 | 24 | |
POPS RICHARD F | director | 31611 0.03% | $135.83 | 0 | 12 | |
SHERWIN STEPHEN A | director | 26504 0.0255% | $135.83 | 0 | 6 | |
ROBERTS EIRY | Chief Medical Officer | 23716 0.0231% | $135.83 | 0 | 27 | |
Cooke Julie | Chief Human Resources Officer | 17976 0.0176% | $135.83 | 0 | 29 | |
Onyia Jude | Chief Scientific Officer | 13128 0.0121% | $135.83 | 0 | 7 | |
Delaet Ingrid | Chief Regulatory Officer | 7507 0.007% | $135.83 | 0 | 14 | |
Boyer David W. | Chief Corp. Affairs Officer | 4895 0.005% | $135.83 | 0 | 15 | |
Sharp Shalini | director | 994 0.001% | $135.83 | 0 | 1 | |
MORROW GEORGE J | director | 0 0% | $135.83 | 0 | 1 | |
Norwalk Leslie V | director | 994 0% | $135.83 | 0 | 2 | |
BVF PARTNERS L P/IL | 10 percent owner | 3527700 3.5905% | $135.83 | 36 | 10 | <0.0001% |
VALE WYLIE W | director | 231372 0.2355% | $135.83 | 0 | 18 | |
Bozigian Haig P. | Chief Development Officer | 154934 0.1577% | $135.83 | 0 | 65 | |
Coughlin Timothy P | Chief Financial Officer | 137961 0.1404% | $135.83 | 0 | 32 | |
HAWRAN PAUL W | Executive VP and CFO | 132000 0.1343% | $135.83 | 0 | 3 | |
VALEUR JENSEN MARGARET E | EVP and General Counsel | 118256 0.1204% | $135.83 | 0 | 7 | |
Grigoriadis Dimitri E. | Chief Research Officer | 82273 0.0837% | $135.83 | 0 | 71 | |
CONLON PAUL J | Vice President Research (Biol) | 57335 0.0584% | $135.83 | 0 | 2 | |
OBrien Christopher Flint | Former Chief Medical Officer | 52223 0.0532% | $135.83 | 0 | 51 | |
Nevinny Corinne H | director | 43283 0.0441% | $135.83 | 0 | 3 | |
Lloyd-Smith Malcolm | Chief Integration Officer | 42337 0.0431% | $135.83 | 0 | 34 | |
STEINMAN LAWRENCE | director | 15500 0.0158% | $135.83 | 0 | 2 | |
RANIERI RICHARD J | Sr. VP, Human Resources | 9667 0.0098% | $135.83 | 0 | 1 | |
SAUNDERS JOHN | Vice President Research (Chem) | 2916 0.003% | $135.83 | 0 | 3 | |
MITCHELL W THOMAS | director | 1000 0.001% | $135.83 | 2 | 7 | +29.05% |
BlackRock | $1.9B | 13.67 | 13.76M | +0.83% | +$15.6M | 0.04 | |
The Vanguard Group | $1.37B | 9.87 | 9.93M | +2.27% | +$30.42M | 0.03 | |
State Street | $550.3M | 3.97 | 3.99M | -1.81% | -$10.12M | 0.02 | |
JPMorgan Chase | $316.54M | 2.28 | 2.3M | +32.24% | +$77.18M | 0.03 | |
Renaissance Technologies | $310.55M | 2.24 | 2.25M | +13.23% | +$36.29M | 0.49 | |
Morgan Stanley | $284.89M | 2.05 | 2.07M | -11.21% | -$35.95M | 0.02 | |
Bellevue Group | $283.55M | 2.04 | 2.06M | -15.41% | -$51.67M | 4.33 | |
T. Rowe Price | $251.13M | 1.81 | 1.82M | +23.28% | +$47.42M | 0.03 | |
Geode Capital Management | $236.01M | 1.7 | 1.71M | +5.58% | +$12.48M | 0.02 | |
Janus Henderson | $190.12M | 1.37 | 1.38M | -11.14% | -$23.84M | 0.1 | |
Dodge & Cox | $174.5M | 1.26 | 1.27M | +0.44% | +$758,560.00 | 0.1 | |
Invesco | $156.81M | 1.13 | 1.14M | +68.73% | +$63.88M | 0.03 | |
Gill Capital Partners | $156.68M | 1.13 | 1.14M | -7.04% | -$11.86M | 2.14 | |
Brown Advisory | $150.1M | 1.08 | 1.09M | -2.25% | -$3.46M | 0.2 | |
ROCK SPRINGS CAPITAL MANAGEMENT, LP | $145.49M | 1.05 | 1.05M | -11.8% | -$19.46M | 3.71 | |
Armistice Capital Llc | $141.19M | 1.02 | 1.02M | -2.31% | -$3.35M | 1.69 | |
Wellington Management Company | $138.44M | 1 | 1M | -16.32% | -$27M | 0.02 | |
AQR Capital | $137.18M | 0.99 | 994,611 | +34.62% | +$35.27M | 0.23 | |
BNY Mellon | $127.07M | 0.92 | 921,335 | -5.9% | -$7.96M | 0.02 | |
Citadel Advisors LLC | $116.03M | 0.84 | 841,318 | +651.18% | +$100.59M | 0.08 | |
Point72 Asset Management | $115.5M | 0.83 | 837,426 | -39.84% | -$76.48M | 0.22 | |
Perceptive Advisors | $110.94M | 0.8 | 804,409 | +197.06% | +$73.6M | 0.07 | |
Franklin Templeton Investments | $109.48M | 0.79 | 793,825 | +2.79% | +$2.97M | 0.03 | |
Polar Capital | $106.96M | 0.77 | 775,556 | -7.21% | -$8.31M | 0.59 | |
Goldman Sachs | $106.99M | 0.77 | 775,727 | +12.16% | +$11.6M | 0.02 | |
Braidwell Lp | $100.71M | 0.73 | 730,209 | +2.1% | +$2.07M | 5.68 | |
Charles Schwab | $100.02M | 0.72 | 725,178 | +5.58% | +$5.29M | 0.02 | |
Northern Trust | $98.62M | 0.71 | 715,068 | -11.42% | -$12.72M | 0.02 | |
HERITAGE ASSET MANAGEMENT INC | $100.88M | 0.71 | 713,525 | -2.04% | -$2.1M | 0.52 | |
Jacobs Levy Equity Management | $98.31M | 0.71 | 712,798 | -5.32% | -$5.53M | 0.44 | |
Deerfield Management | $95.3M | 0.69 | 691,004 | -22.94% | -$28.37M | 1.84 | |
Ubs Asset Management Americas Inc | $82.67M | 0.6 | 599,424 | -2.92% | -$2.49M | 0.03 | |
CalPERS | $80.08M | 0.58 | 580,617 | -1.08% | -$873,447.36 | 0.06 | |
Bank of America | $78.16M | 0.56 | 566,713 | +19.82% | +$12.93M | 0.01 | |
Legal & General | $74.49M | 0.54 | 540,106 | -6.38% | -$5.07M | 0.02 | |
Avidity Partners Management Lp | $73.99M | 0.53 | 536,500 | -18.46% | -$16.76M | 2.69 | |
GW&K Investment Management | $72.8M | 0.53 | 527,874 | -1.51% | -$1.12M | 0.64 | |
First Trust | $72.63M | 0.52 | 526,582 | -10.86% | -$8.85M | 0.07 | |
Fiera Capital | $70.55M | 0.51 | 511,542 | -1.03% | -$734,148.15 | 0.21 | |
Allspring Global Investments | $69.88M | 0.5 | 506,666 | +23.55% | +$13.32M | 0.11 | |
IEQ Capital | $69.8M | 0.5 | 506,113 | +4.82% | +$3.21M | 1.01 | |
Westfield Capital Management Co Lp | $69.4M | 0.5 | 503,193 | -15.35% | -$12.58M | 0.37 | |
Millennium Management LLC | $62.78M | 0.45 | 455,220 | -33.93% | -$32.24M | 0.05 | |
OrbiMed | $58.35M | 0.42 | 423,100 | -18.52% | -$13.27M | 1.19 | |
Ameriprise Financial | $55.91M | 0.4 | 405,347 | -4.79% | -$2.81M | 0.02 | |
PRIMECAP Management Co | $55.08M | 0.4 | 399,380 | +0.27% | +$145,781.44 | 0.04 | |
Lord Abbett | $53.96M | 0.39 | 391,244 | +732.77% | +$47.48M | 0.19 | |
APG Asset Management | $48.16M | 0.38 | 377,118 | -1.42% | -$692,920.29 | 0.08 | |
Amundi | $47.94M | 0.36 | 361,672 | +6.31% | +$2.84M | 0.02 | |
Deutsche Bank | $49.63M | 0.36 | 359,856 | +6.76% | +$3.14M | 0.02 |